Twist Bioscience Corporation — Earnings Quality Grade F
TWST · Healthcare
Major red flags
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO increased by 15 days
AR growth 63.4% exceeds revenue growth 20.3%
Revenue 20.3%, CFFO 25.7%. Cash follows revenue
Expense Quality
Inventory 17.6% vs COGS 3.3%. Normal
CapEx growth 451.7% is >2x revenue growth 20.3%
SG&A/Gross Profit = 129.3%, exceeds 70%
Gross margin swung +8.1pp (42.6% → 50.7%)
Cash Flow Quality
CFFO < Net Income for 3 consecutive years
FCF is negative ($-0.1B)
Accruals ratio = -4.7%. Low accruals
Cash $0.2B covers debt $0.1B
Balance Sheet Health
Goodwill+Intangibles $0.1B = 20% of equity. Manageable
Debt/EBITDA = -0.7x. Healthy
Other assets grew 66.0% vs revenue 20.3%
No write-off data
Acquisition Risk
FCF after acquisitions negative for 3 years
Goodwill+Intangibles change -5% YoY. Normal
Manipulation Score
M-Score = -2.15 (grey zone)
Portfolio monitoring
Monitor TWST continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25